Continuing medical educationNeurofibromatosis type 1
Section snippets
Genetics of neurofibromatosis type 1
Key points NF1 is an autosomal dominant disorder, with a nearly even split between spontaneous and inherited mutations. Segmental NF1 represents mosaicism.
Pathogenesis of neurofibromatosis type 1
Key point The NF1 gene codes for neurofibromin, a tumor suppressor protein.
Neurofibromin, the NF1 gene protein product, is a tumor suppressor expressed in many cells, primarily in neurons, glial, Schwann cells, and early in melanocyte development.20 This protein is a regulator of Ras guanosine triphosphatase activity (GTPase-activating protein) and as such serves as a regulator of the signals for cell proliferation and differentiation5 (Fig 1). The loss of function of neurofibromin may therefore remove
Diagnosis
Key points Some diagnostic criteria may not manifest until later in life. Clinical diagnostic criteria are not as sensitive in very young children.
Cutaneous manifestations
Key point Patients with NF1 may develop a variety of skin findings.
Dermatologists should quickly recognize not only the salient skin features but also the less common cutaneous findings, because these latter aspects may be the source of a referral. The common and uncommon cutaneous features are provided in Table II. The following is a brief explanation of these findings. Additional details are provided on the more rare skin manifestations and noncutaneous findings that are easy to detect on physical
Noncutaneous manifestations
Key points Dermatologists should screen for bone abnormalities that may require referral to orthopedics. Learning disabilities are the most common complication in children with NF1.
NF1 has the ability to affect nearly every organ system. While this paper is focused on the cutaneous manifestations, consideration must also be given to findings that the dermatologist may note on a physical examination or gather from the patient's history so that appropriate steps may be taken. A summary of these findings is
Management and future directions
The dermatologist has a primary role in recognizing and differentiating NF1 from other conditions based on a careful skin examination, making appropriate referrals once the diagnosis is made, and managing symptomatic or disfiguring cutaneous neurofibromas. Currently, neurofibromas are amenable only to surgical removal. Symptomatic (ie, painful and bleeding) neurofibromas are most commonly removed but, depending on the community, this may not be handled by dermatology. Several studies have
Summary
NF1 is a multisystem disorder requiring management by multiple disciplines, often coordinated through a primary care physician or a geneticist. The dermatologist has a role not only in the diagnosis of NF1 and differentiating it from other similar disorders but also in the recognition of rare but associated skin manifestations. Genetic testing has increased our ability to make the diagnosis in uncertain cases, but has not allowed us to predict a particular patient's natural history based on the
References (95)
Neurofibromatosis: clinical heterogeneity
Curr Probl Cancer
(1982)- et al.
Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus
Cell
(1990) - et al.
Gonosomal mosaicism for a nonsense mutation (R1947X) in the NF1 gene in segmental neurofibromatosis type 1
J Invest Dermatol
(2005) - et al.
Molecular dissection of isolated disease features in mosaic neurofibromatosis type 1
Am J Hum Genet
(2007) - et al.
Somatic mutation analysis in NF1 café-au-lait spots reveals two NF1 hits in the melanocytes
J Invest Dermatol
(2008) - et al.
Plexiform and dermal neurofibromas and pigmentation are caused by NF1 loss in desert hedgehog-expressing cells
Cancer Cell
(2008) - et al.
Elevated risk for MPNST in NF1 microdeletion patients
Am J Hum Genet
(2003) - et al.
An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation
Am J Hum Genet
(2007) Pathophysiology of neurofibromatosis: IV. Dermatologic insights into heterogeneity and pathogenesis
J Am Acad Dermatol
(1980)- et al.
The diagnostic value of café-au-lait macules
J Am Acad Dermatol
(1999)
Juvenile chronic granulocytic leukemia, juvenile xanthogranulomas, and neurofibromatosis. Case report and review of the literature
J Am Acad Dermatol
Three cases of subungual glomus tumors with von Recklinghausen neurofibromatosis
J Am Acad Dermatol
Iris melanoma in a patient with neurofibromatosis
Surv Ophthalmol
Nevus anemicus
J Am Acad Dermatol
Localized pruritus: a presenting symptom of a spinal cord tumor in a child with features of neurofibromatosis
J Am Acad Dermatol
Recent insights into bone development, homeostasis, and repair in type 1 neurofibromatosis (NF1)
Bone
Double inactivation of NF1 in tibial pseudoarthrosis
Am J Hum Genet
Cognitive profile of neurofibromatosis type 1
Semin Pediatr Neurol
Von Recklinghausen neurofibromatosis: incidence of iris hamartomas
Ophthalmology
Optic gliomas in children with neurofibromatosis type 1
J Pediatr
Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study
J Pediatr
Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromas
Pediatr Neurol
Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex
Am J Kidney Dis
Nf1-dependent tumors require a microenvironment containing Nf1+/− and c-kit-dependent bone marrow
Cell
The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1
Curr Biol
A clinical, pathological and genetic study of multiple neurofibromatosis
Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype
Nat Genet
Neurofibromatosis: A handbook for patients, families, and health care professionals
Penetrance of von Recklinghausen neurofibromatosis: a distinction between predecessors and descendants
Am J Hum Genet
Pathophysiology of neurofibromatosis type 1
Ann Intern Med
Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects
Hum Mutat
Recurrent mutations in the NF1 gene are common among neurofibromatosis type 1 patients
J Med Genet
Distribution of 13 truncating mutation in the neurofibromatosis 1 gene
Hum Mol Genet
The clinical and diagnostic implications of mosaicism in the neurofibromatoses
Neurology
Neurofibromatosis type 1 due to germ-line mosaicism in a clinically normal father
N Engl J Med
Neurofibromatosis type 1 in a child of a parent with segmental neurofibromatosis (NF-5)
Neurofibromatosis
The classification of atypical forms of neurofibromatosis
Schweiz Med Wochenschr
Neurofibromatosis: a handbook for patients, families, and health care professionals
What is segmental neurofibromatosis?
Br J Dermatol
Segmental neurofibromatosis of the sciatic nerve: case report
Neurosurgery
Segmental neurofibromatosis
South Med J
Regulated expression of neurofibromin in migrating neural crest cells of avian embryos
J Neurobiol
The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2
JAMA
Use of the National Institutes of Health criteria for diagnosis of neurofibromatosis 1 in children
Pediatrics
Screening 500 unselected neurofibromatosis 1 patients for deletions of the NF1 gene
Hum Mutat
Familial neurofibromatosis 1 microdeletions: cosegregation with distinct facial phenotype and early onset of cutaneous neurofibromata
Am J Med Genet
Familial café-au-lait spots: a variant of neurofibromatosis type 1
J Med Genet
Cited by (0)
Funding sources: None.
Conflicts of interest: The authors, editors, and peer reviewers have no relevant financial relationships.